Alexion (ALXN) Misses on Q1 Earnings, Maintains Outlook – Tale of the Tape
Alexion Pharmaceuticals (ALXN) focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is sole marketed product of this Cheshire, CT based company.
In this scenario, investor focus remains on Soliris performance and pipeline progress. Alexion is expecting seven product approvals through 2018 including Strensiq, ALXN 1101 and Soliris’ label expansion into indications such as antibody-mediated rejection, neuromyelitis optica and the prevention of delayed graft function in renal transplant patients.
Alexion has a mixed earnings track record with the company delivering positive earnings surprises in two of the last four quarters with an average surprise of 8.63%.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion’s fourth quarter earnings missed expectations. Our consensus called for EPS of $1.18, and the company reported EPS of $1.07 (these figures include stock-based compensation expense).
Revenue: Revenues were slightly above expectations. Alexion posted revenues of $600.3 million, compared to our consensus estimate of $592 million.
Key Stats: Soliris continues to drive revenues at Alexion. The company reiterated it’s 2015 outlook. The company expects adjusted earnings per share in the range of $5.60 to $5.80 per share in 2015. Foreign exchange translations are expected to negatively impact earnings by 35 cents. The Zacks Consensus Estimate for 2015 is $5.32.
Check back later for our full write up on this Alexion earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report